MedTrace Logo

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2026-04-02

No results posted yet for this study

Summary

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Conditions

  • Low Grade Serous Ovarian Cancer

Interventions

DRUG

avutometinib

Avutometinib: administered orally

DRUG

Defactinib

Defactinib: administered orally

DRUG

Pegylated liposomal doxorubicin

administered intravenously

DRUG

Paclitaxel

administered intravenously

DRUG

Letrozole

administered orally

DRUG

Anastrozole

administered orally

Sponsors & Collaborators

  • GOG Foundation

    collaborator NETWORK

  • European Network of Gynaecological Oncological Trial Groups (ENGOT)

    collaborator OTHER

  • Australia New Zealand Gynaecological Oncology Group

    collaborator OTHER

  • Korean Gynecologic Oncology Group

    collaborator OTHER

  • Verastem, Inc.

    lead INDUSTRY

Principal Investigators

  • Rachel Grisham, MD · GOG Foundation

  • Susana Banerjee, MBBS, MA, PhD · European Network of Gynecological Oncological Trial Groups (ENGOT)

  • Craig Berman Verastem Medical Monitor · [email protected]

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-18
Primary Completion
2028-10-15
Completion
2031-02-09
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Denmark
  • France
  • Germany
  • Ireland
  • Italy
  • Japan
  • Netherlands
  • New Zealand
  • Poland
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06072781 on ClinicalTrials.gov